Enter Your Practice Information

Yes No

Yes No


Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.


  Sign up now for:
Become a Member

Journal January 2009 (Vol 31, No 1)

NOTE: You have already passed this course.
NOTE: This course is no longer valid for accreditation purposes.

Immunosuppressive Therapy for Canine Immune-Mediated Hemolytic Anemia CE Article #3 by Suliman Al-Ghazlat , BVSc, DACVIM

1. Which statement regarding dogs with IMHA is correct?
2. Which statement regarding glucocorticoid therapy for treating IMHA is correct?
3. Which statement regarding immunosuppressive agents used to treat canine IMHA is correct?
4. Which statement regarding the mechanism of action of immunosuppressive agents is incorrect?
5. Which is not a reported side effect of cyclosporine therapy in dogs?
6. Which is not a side effect of azathioprine therapy in dogs?
7. Which is not a side effect of glucocorticoids?
8. Which patient is the most suitable candidate for hIVIG treatment?
9. Which immunosuppressive therapy is unlikely to be effective in the first 2 weeks of treating IMHA?
10. In dogs with IMHA, administration of which immunosuppressive drug has been associated with a worse outcome in retrospective studies?
Stay on top of all our latest content — sign up for the Vetlearn newsletters.
  • More